Huseyin Saffet Bekoz
Overview
Explore the profile of Huseyin Saffet Bekoz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yigit Kaya S, Melek E, Mutlu Y, Bekoz H, Maral S, Kaynar L, et al.
Ann Hematol
. 2025 Feb;
PMID: 40016397
No abstract available.
2.
Ozalp Y, Shehabie H, Tekin M, Yigit Kaya S, Bekoz H, Maral S, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1201.
PMID: 39448907
Background: Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection that primarily affects immunocompromised individuals. Typical symptoms of PJP include the subacute onset of dyspnea, nonproductive cough, and low-grade fever. In...
3.
Mutlu Y, Aydin B, Erdogan C, Kizilaslan D, Bekoz H, Gemici A, et al.
Indian J Hematol Blood Transfus
. 2023 Apr;
39(2):167-172.
PMID: 37006979
Introduction: To identify new clinical and biologic parameters associated with short-term survival in allogeneic or autologous hematopoietic stem cell transplantation (HSCT) patients who were admitted to the intensive care unit...
4.
Dal M, Ulu B, Uzay A, Akay O, Besisik S, Yenerel M, et al.
Ann Hematol
. 2022 Nov;
102(1):133-140.
PMID: 36401621
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL...
5.
Erdogan E, Yalcin K, Hemsinlioglu C, Sezgin A, Seyis U, Kancagi D, et al.
Turk J Haematol
. 2022 Jul;
39(3):206-210.
PMID: 35848614
Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial...
6.
Bozdag S, Seval G, Hindilerden I, Hindilerden F, Andic N, Baydar M, et al.
Turk J Haematol
. 2021 Sep;
39(1):43-54.
PMID: 34521187
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such...
7.
Gemici A, Ozkalemkas F, Dogu M, Tekinalp A, Alacacioglu I, Guney T, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Jun;
21(8):e686-e692.
PMID: 34059487
Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in...
8.
Gemici A, Bilgen H, Erdogan C, Kansu A, Olmuscelik O, Bekoz H, et al.
Turk J Med Sci
. 2020 Oct;
50(8):1781-1785.
PMID: 33078604
Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19....
9.
Ceylan B, Yilmaz M, Bekoz H, Ramadan S, Akan G, Mert A
Infez Med
. 2019 Mar;
27(1):85-92.
PMID: 30882385
Invasive aspergillosis is a severe infection that generally involves the lungs. Primary gastrointestinal aspergillosis is the least common form of invasive aspergillosis. A patient aged 65 years developed a febrile...
10.
Arslan F, Karagoz E, Bekoz H, Ceylan B, Mert A
Infez Med
. 2017 Sep;
25(3):277-280.
PMID: 28956548
Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening catastrophic and rarely seen complication of EBV infection especially in adults. While typical presentation of EBV infection is easily diagnosed as mononucleosis...